CN115197899A - 一种可调控内皮祖细胞分化趋势涂覆层的制备方法 - Google Patents
一种可调控内皮祖细胞分化趋势涂覆层的制备方法 Download PDFInfo
- Publication number
- CN115197899A CN115197899A CN202210854361.7A CN202210854361A CN115197899A CN 115197899 A CN115197899 A CN 115197899A CN 202210854361 A CN202210854361 A CN 202210854361A CN 115197899 A CN115197899 A CN 115197899A
- Authority
- CN
- China
- Prior art keywords
- cwc
- hydroxydopamine
- grafted
- coating layer
- sulfone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000003511 endothelial effect Effects 0.000 title claims abstract description 34
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 25
- 239000011247 coating layer Substances 0.000 title claims abstract description 23
- 230000004069 differentiation Effects 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- LCAINUZZHIZKKS-UHFFFAOYSA-N 5-Hydroxydopamine Chemical compound NCCC1=CC(O)=C(O)C(O)=C1 LCAINUZZHIZKKS-UHFFFAOYSA-N 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 15
- 239000000463 material Substances 0.000 claims abstract description 12
- 239000011248 coating agent Substances 0.000 claims abstract description 9
- 238000000576 coating method Methods 0.000 claims abstract description 9
- 125000003277 amino group Chemical group 0.000 claims abstract description 8
- 229920003169 water-soluble polymer Polymers 0.000 claims abstract description 8
- 239000000758 substrate Substances 0.000 claims abstract description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 20
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 17
- 239000003054 catalyst Substances 0.000 claims description 12
- 150000001718 carbodiimides Chemical class 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 125000000542 sulfonic acid group Chemical group 0.000 claims description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 8
- 239000000376 reactant Substances 0.000 claims description 8
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 7
- KECOIASOKMSRFT-UHFFFAOYSA-N 2-amino-4-(3-amino-4-hydroxyphenyl)sulfonylphenol Chemical compound C1=C(O)C(N)=CC(S(=O)(=O)C=2C=C(N)C(O)=CC=2)=C1 KECOIASOKMSRFT-UHFFFAOYSA-N 0.000 claims description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 6
- 239000000178 monomer Substances 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000002953 phosphate buffered saline Substances 0.000 claims description 6
- PLVUIVUKKJTSDM-UHFFFAOYSA-N 1-fluoro-4-(4-fluorophenyl)sulfonylbenzene Chemical compound C1=CC(F)=CC=C1S(=O)(=O)C1=CC=C(F)C=C1 PLVUIVUKKJTSDM-UHFFFAOYSA-N 0.000 claims description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 4
- 238000006068 polycondensation reaction Methods 0.000 claims description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims description 4
- 229960003638 dopamine Drugs 0.000 claims description 3
- HNXGGWNCFXZSAI-UHFFFAOYSA-N 2-morpholin-2-ylethanesulfonic acid Chemical compound OS(=O)(=O)CCC1CNCCO1 HNXGGWNCFXZSAI-UHFFFAOYSA-N 0.000 claims description 2
- QVBOWRMZONBBIK-UHFFFAOYSA-N 4-(dimethylamino)-n-[5-(1h-indol-4-yl)pyridin-3-yl]butanamide Chemical compound CN(C)CCCC(=O)NC1=CN=CC(C=2C=3C=CNC=3C=CC=2)=C1 QVBOWRMZONBBIK-UHFFFAOYSA-N 0.000 claims description 2
- ILRSHIWNUADHDP-UHFFFAOYSA-N 5-(3-amino-4-fluorophenyl)sulfonyl-2-fluoroaniline Chemical compound C1=C(F)C(N)=CC(S(=O)(=O)C=2C=C(N)C(F)=CC=2)=C1 ILRSHIWNUADHDP-UHFFFAOYSA-N 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000009881 electrostatic interaction Effects 0.000 claims description 2
- 125000001207 fluorophenyl group Chemical group 0.000 claims description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims description 2
- 229960002317 succinimide Drugs 0.000 claims description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 2
- 230000024245 cell differentiation Effects 0.000 claims 2
- DYDXGSCSCUFMRW-UHFFFAOYSA-N 3-amino-4-(2-amino-4-hydroxyphenyl)sulfonylphenol Chemical compound NC1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1N DYDXGSCSCUFMRW-UHFFFAOYSA-N 0.000 claims 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 claims 1
- 230000035755 proliferation Effects 0.000 abstract description 11
- 230000001105 regulatory effect Effects 0.000 abstract description 10
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 8
- 238000005516 engineering process Methods 0.000 abstract description 6
- 210000004509 vascular smooth muscle cell Anatomy 0.000 abstract description 5
- 230000000975 bioactive effect Effects 0.000 abstract description 4
- 239000000853 adhesive Substances 0.000 abstract description 3
- 230000001070 adhesive effect Effects 0.000 abstract description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 210000005167 vascular cell Anatomy 0.000 abstract description 2
- 230000001276 controlling effect Effects 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 15
- 210000002889 endothelial cell Anatomy 0.000 description 13
- 230000006872 improvement Effects 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 239000010410 layer Substances 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 6
- VPWNQTHUCYMVMZ-UHFFFAOYSA-N 4,4'-sulfonyldiphenol Chemical compound C1=CC(O)=CC=C1S(=O)(=O)C1=CC=C(O)C=C1 VPWNQTHUCYMVMZ-UHFFFAOYSA-N 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 3
- KDRWFAHFRRKETF-UHFFFAOYSA-L disodium;2-fluoro-5-(4-fluoro-3-sulfonatophenyl)sulfonylbenzenesulfonate Chemical compound [Na+].[Na+].C1=C(F)C(S(=O)(=O)[O-])=CC(S(=O)(=O)C=2C=C(C(F)=CC=2)S([O-])(=O)=O)=C1 KDRWFAHFRRKETF-UHFFFAOYSA-L 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 208000037803 restenosis Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WJCJURROHWABCR-UHFFFAOYSA-N benzenesulfonylbenzene;sodium Chemical compound [Na].C=1C=CC=CC=1S(=O)(=O)C1=CC=CC=C1 WJCJURROHWABCR-UHFFFAOYSA-N 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 239000002345 surface coating layer Substances 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C12N5/0692—Stem cells; Progenitor cells; Precursor cells
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D187/00—Coating compositions based on unspecified macromolecular compounds, obtained otherwise than by polymerisation reactions only involving unsaturated carbon-to-carbon bonds
- C09D187/005—Block or graft polymers not provided for in groups C09D101/00 - C09D185/04
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/80—Neurotransmitters; Neurohormones
- C12N2501/815—Dopamine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210854361.7A CN115197899B (zh) | 2022-07-20 | 2022-07-20 | 一种可调控内皮祖细胞分化趋势涂覆层的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210854361.7A CN115197899B (zh) | 2022-07-20 | 2022-07-20 | 一种可调控内皮祖细胞分化趋势涂覆层的制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115197899A true CN115197899A (zh) | 2022-10-18 |
| CN115197899B CN115197899B (zh) | 2023-06-30 |
Family
ID=83581930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210854361.7A Active CN115197899B (zh) | 2022-07-20 | 2022-07-20 | 一种可调控内皮祖细胞分化趋势涂覆层的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115197899B (zh) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997004809A1 (en) * | 1995-07-28 | 1997-02-13 | Aegis Biosciences L.L.C. | Sulfonated multiblock copolymer and uses therefor |
| WO2003011355A1 (fr) * | 2001-07-27 | 2003-02-13 | Sofradim Production | Endoprothese vasculaire recouverte d'un derive fonctionnalise de dextrane |
| EP1537858A1 (en) * | 2003-12-04 | 2005-06-08 | Vectron Therapeutics AG | Drug delivery vehicles and uses thereof |
| US20070218102A1 (en) * | 2006-03-15 | 2007-09-20 | Surmodics, Inc. | Biodegradable hydrophobic polysaccharide-based coatings |
| WO2012008837A2 (en) * | 2010-07-16 | 2012-01-19 | X-Flow Bv | Grafted poly(arylsulfone) and a process for grafting a poly(arylsulfone) |
| CN103330960A (zh) * | 2013-06-26 | 2013-10-02 | 西南交通大学 | 一种具有内皮仿生功能涂层的制备方法 |
| WO2018191681A1 (en) * | 2017-04-13 | 2018-10-18 | Orbusneich Medical, Inc. | Medical devices coated with polydopamine and antibodies |
| CN108785748A (zh) * | 2018-07-05 | 2018-11-13 | 四川大学 | 一种具有超亲水性能的多功能心血管涂层材料及其制备方法 |
| US20190365954A1 (en) * | 2018-05-30 | 2019-12-05 | Wisconsin Alumni Research Foundation | Promoting endothelial cell affinity and antithrombogenicity of polytetrafluoroethylene (ptfe) by mussel-inspired modification and rgd/heparin grafting |
| CN112870437A (zh) * | 2021-01-18 | 2021-06-01 | 成都鼎峰前瞻科技有限公司 | 具有抗凝抗增生及促内皮化的功能材料、其制备方法和应用 |
| CN113559720A (zh) * | 2021-07-12 | 2021-10-29 | 武汉理工大学 | 拥有仿肝素改性涂层的聚醚砜血液透析膜及其制备方法、应用 |
-
2022
- 2022-07-20 CN CN202210854361.7A patent/CN115197899B/zh active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997004809A1 (en) * | 1995-07-28 | 1997-02-13 | Aegis Biosciences L.L.C. | Sulfonated multiblock copolymer and uses therefor |
| WO2003011355A1 (fr) * | 2001-07-27 | 2003-02-13 | Sofradim Production | Endoprothese vasculaire recouverte d'un derive fonctionnalise de dextrane |
| EP1537858A1 (en) * | 2003-12-04 | 2005-06-08 | Vectron Therapeutics AG | Drug delivery vehicles and uses thereof |
| US20070218102A1 (en) * | 2006-03-15 | 2007-09-20 | Surmodics, Inc. | Biodegradable hydrophobic polysaccharide-based coatings |
| WO2012008837A2 (en) * | 2010-07-16 | 2012-01-19 | X-Flow Bv | Grafted poly(arylsulfone) and a process for grafting a poly(arylsulfone) |
| CN103330960A (zh) * | 2013-06-26 | 2013-10-02 | 西南交通大学 | 一种具有内皮仿生功能涂层的制备方法 |
| WO2018191681A1 (en) * | 2017-04-13 | 2018-10-18 | Orbusneich Medical, Inc. | Medical devices coated with polydopamine and antibodies |
| US20190365954A1 (en) * | 2018-05-30 | 2019-12-05 | Wisconsin Alumni Research Foundation | Promoting endothelial cell affinity and antithrombogenicity of polytetrafluoroethylene (ptfe) by mussel-inspired modification and rgd/heparin grafting |
| CN108785748A (zh) * | 2018-07-05 | 2018-11-13 | 四川大学 | 一种具有超亲水性能的多功能心血管涂层材料及其制备方法 |
| CN112870437A (zh) * | 2021-01-18 | 2021-06-01 | 成都鼎峰前瞻科技有限公司 | 具有抗凝抗增生及促内皮化的功能材料、其制备方法和应用 |
| CN113559720A (zh) * | 2021-07-12 | 2021-10-29 | 武汉理工大学 | 拥有仿肝素改性涂层的聚醚砜血液透析膜及其制备方法、应用 |
Non-Patent Citations (4)
| Title |
|---|
| CHONG CHENG 等: "Progress in heparin and heparin-like/mimicking polymer-functionalized biomedical membranes", 《JOURNAL OF MATERIALS CHEMISTRY B》, vol. 2, no. 44, pages 7649 - 7672 * |
| L.R. WANG 等: "Direct synthesis of heparin-like poly(ether sulfone) polymer and its blood compatibility", 《ACTA BIOMATERIALIA》, vol. 9, no. 11, pages 8851 - 8863 * |
| LANG MA 等: "Mussel-inspired self-coating at macro-interface with improved biocompatibility and bioactivity via dopamine grafted heparin-like polymers and heparin", 《JOURNAL OF MATERIALS CHEMISTRY B》, vol. 2, no. 4, pages 363 - 375, XP055926168, DOI: 10.1039/C3TB21388A * |
| LINGREN WANG 等: "Layer by layer assembly of sulfonic poly(ether sulfone) as heparin-mimicking coatings: scalable fabrication of super-hemocompatible and antibacterial membranes", 《JOURNAL OF MATERIALS CHEMISTRY B》, vol. 3, no. 7, pages 1391 - 1404 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115197899B (zh) | 2023-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | The unprecedented biodegradable polyzwitterion: a removal‐free patch for accelerating infected diabetic wound healing | |
| US6696575B2 (en) | Biodegradable, electrically conducting polymer for tissue engineering applications | |
| Nuttelman et al. | Synthesis and characterization of photocrosslinkable, degradable poly (vinyl alcohol)-based tissue engineering scaffolds | |
| US8241655B2 (en) | Coatings for medical articles including natural biodegradable polysaccharides | |
| CN101905034B (zh) | 生物多糖自组装修饰的壳聚糖抗菌生物材料的制备方法 | |
| CN103330960A (zh) | 一种具有内皮仿生功能涂层的制备方法 | |
| JP5507566B2 (ja) | 血管壁臨時骨格(補助材)用の生分解性ブレンド | |
| JP2012503068A (ja) | 生分解性一酸化窒素発生ポリマー及び関連医用デバイス | |
| CN101703813A (zh) | 利用内源性no供体构建抗凝血性血管支架材料的方法 | |
| Yang et al. | Polydopamine-mediated long-term elution of the direct thrombin inhibitor bivalirudin from TiO 2 nanotubes for improved vascular biocompatibility | |
| CN102698322B (zh) | 一种富含氨基、羧基和醌基的多类功能团的生物医用材料制备方法 | |
| Fathi et al. | Enhancing the mechanical properties and physical stability of biomimetic polymer hydrogels for micro-patterning and tissue engineering applications | |
| Yu et al. | Development of Poly (1, 8-octanediol-co-citrate-co-ascorbate) elastomers with enhanced ascorbate performance for use as a graft coating to prevent neointimal hyperplasia | |
| Liu et al. | Preparation and degradation characteristics of biodegradable elastic poly (1, 3-trimethylene carbonate) network | |
| CN115197899B (zh) | 一种可调控内皮祖细胞分化趋势涂覆层的制备方法 | |
| CN119656390B (zh) | 促进心脏瓣膜内皮化的方法及人造心脏瓣膜 | |
| CN119113231B (zh) | 一种抗血管再狭窄的活性氧响应性水凝胶涂层及其制备方法和应用 | |
| CN111437442B (zh) | 一种镁基医用植入物表面用可降解电泳涂层的制备方法 | |
| Li et al. | Constructing Immunomodulator Biosynthesis Factory in Grafting‐From DNA Hydrogel for Heart Valve Regeneration | |
| US20200139010A1 (en) | Gradient Coatings of Biopeptides That Promote Endothelial Cells Selective Adhesion and Directional Migration and Methods of Using the Same | |
| CN115337470B (zh) | 一种内皮细胞友好型抗内膜增生涂覆层的制备方法 | |
| CN115785403B (zh) | 一种苹果酸基生物材料及其制备方法和应用 | |
| CN115337472B (zh) | 一种涂层组合物、涂层及其制备方法、医疗器械 | |
| JP2004506690A5 (zh) | ||
| CN100393368C (zh) | 一种细胞培养和脱附用的智能膜及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20241218 Address after: Room C902, 9th Floor, Century Life Port, No.12 Lantian Road West, Meilan District, Haikou City, Hainan Province, China 570100 Patentee after: Hainan Kangmaoxin Pharmaceutical Technology Co.,Ltd. Country or region after: China Address before: 223000 No.1, Meicheng East Road, Huaian Economic and Technological Development Zone, Jiangsu Province Patentee before: HUAIYIN INSTITUTE OF TECHNOLOGY Country or region before: China |
|
| TR01 | Transfer of patent right |